文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新辅助放化疗后局部晚期直肠癌直肠MRI变量对病理完全缓解的预测价值

Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy.

作者信息

Li Ganbin, An Yang, Zhang Xiao, Wang Chentong, Qiu Xiaoyuan, Zhang Guannan, Niu Beizhan, Xu Lai, Lu Junyang, Wu Bin, Xiao Yi, Lin Guole

机构信息

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Dong Cheng District, Beijing, 100730, China.

出版信息

Int J Colorectal Dis. 2025 Feb 17;40(1):42. doi: 10.1007/s00384-024-04801-w.


DOI:10.1007/s00384-024-04801-w
PMID:39960557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11832599/
Abstract

PURPOSE: To evaluate the predictive value of MRI-determined variables for pathological complete response (pCR) in locally advanced rectal cancer (LARC) patients following neoadjuvant chemoradiotherapy (NCRT). METHODS: Clinical data were collected from patients who received NCRT between January 2019 and 2022. Patients with rectal adenocarcinoma, cT3-4N0, or TanyN1-2 were included. pCR was defined pT0N0. Patients were divided into pCR and non-pCR group. Logistic regression analysis was performed to identify factors associated with pCR. A nomogram model was constructed to validate its predictive ability and accuracy. RESULTS: A total of 585 patients were identified, with 144 (24.6%) in the pCR group and 441 (75.4%) in the non-pCR group. Patients with mrT2-3 (OR 6.41, P < 0.001), mrN0 (OR 2.17, P < 0.001), circumferential occupation range < 1/2 cycles (OR 2.11, P < 0.001), tumor vertical diameter < 36 mm (OR 2.10, P < 0.001), negative mesorectal fascia (OR 3.21, P < 0.001), and extramural vascular invasion (OR 5.68, P < 0.001) were more likely to achieve higher pCR rates. Logistic regression analysis revealed that mrT2-3 (OR 3.50, P < 0.001), tumor vertical diameter < 36 mm (OR 2.57, P < 0.001), and negative extramural vascular invasion (OR 4.03, P < 0.001) were independent protective factors for pCR. A nomogram was developed to predict pCR, achieving a C-index of 0.778. CONCLUSION: Patients with mrT2-3, tumor vertical diameter < 36 mm, and negative extramural vascular invasion are more likely to achieve pCR after NCRT.

摘要

目的:评估磁共振成像(MRI)测定的变量对局部晚期直肠癌(LARC)患者新辅助放化疗(NCRT)后病理完全缓解(pCR)的预测价值。 方法:收集2019年1月至2022年期间接受NCRT的患者的临床资料。纳入直肠腺癌、cT3 - 4N0或TanyN1 - 2患者。pCR定义为pT0N0。患者分为pCR组和非pCR组。进行逻辑回归分析以确定与pCR相关的因素。构建列线图模型以验证其预测能力和准确性。 结果:共纳入585例患者,pCR组144例(24.6%),非pCR组441例(75.4%)。mrT2 - 3(比值比[OR] 6.41,P < 0.001)、mrN0(OR 2.17,P < 0.001)、环周受累范围< 1/2周期(OR 2.11,P < 0.001)、肿瘤垂直径< 36 mm(OR 2.10,P < 0.001)、直肠系膜筋膜阴性(OR 3.21,P < 0.001)及壁外血管侵犯阴性(OR 5.68,P < 0.001)的患者更有可能获得更高的pCR率。逻辑回归分析显示,mrT2 - 3(OR 3.50,P < 0.001)、肿瘤垂直径< 36 mm(OR 2.57,P < 0.00)及壁外血管侵犯阴性(OR 4.03,P < 0.001)是pCR的独立保护因素。开发了一个列线图来预测pCR,C指数为0.778。 结论:mrT2 - 3、肿瘤垂直径< 36 mm及壁外血管侵犯阴性的患者在NCRT后更有可能实现pCR。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/618c8104f7f0/384_2024_4801_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/40c8a8bb34e9/384_2024_4801_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/b04c5f481f93/384_2024_4801_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/226a76a7cd10/384_2024_4801_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/618c8104f7f0/384_2024_4801_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/40c8a8bb34e9/384_2024_4801_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/b04c5f481f93/384_2024_4801_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/226a76a7cd10/384_2024_4801_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18e9/11832599/618c8104f7f0/384_2024_4801_Fig4_HTML.jpg

相似文献

[1]
Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy.

Int J Colorectal Dis. 2025-2-17

[2]
Radiomic Features of Mesorectal Fat as Indicators of Response in Rectal Cancer Patients Undergoing Neoadjuvant Therapy.

Tomography. 2025-4-7

[3]
Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade.

Cancer Radiother. 2024-8

[4]
Developing a prediction model based on MRI for pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Abdom Radiol (NY). 2019-9

[5]
[Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2020-3-25

[6]
[Development of a nomogram for predicting pathological complete response after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2025-3-25

[7]
Predicting disease-free survival in locally advanced rectal cancer using a prognostic model based on pretreatment b-value threshold map and postoperative pathologic features.

Jpn J Radiol. 2025-2

[8]
Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer.

World J Gastroenterol. 2019-1-7

[9]
[Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2024-4-25

[10]
Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Eur Radiol. 2018-8-20

引用本文的文献

[1]
Rectal-RadioSAM: Large model-assisted multi-parametric magnetic resonance imaging pipeline for predicting response to neoadjuvant chemoradiotherapy in rectal cancer without human intervention.

Phys Imaging Radiat Oncol. 2025-6-20

[2]
Correspondence for the article titled "Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy".

Int J Colorectal Dis. 2025-6-4

本文引用的文献

[1]
Prediction of pathological complete response and prognosis in locally advanced rectal cancer.

World J Gastrointest Oncol. 2024-6-15

[2]
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Ann Oncol. 2024-10

[3]
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.

Ann Oncol. 2024-10

[4]
Prediction of pathologic complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.

Front Oncol. 2024-3-11

[5]
Image-based artificial intelligence for the prediction of pathological complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review and meta-analysis.

Radiol Med. 2024-4

[6]
The clinical relevance of adjuvant chemotherapy in locally advanced rectal cancer patients achieving near pathological complete response following neoadjuvant chemoradiotherapy: Insights from ypT stage.

Eur J Surg Oncol. 2024-4

[7]
Pretreatment MRI-detected extramural venous invasion as a prognostic and predictive biomarker for neoadjuvant chemoradiotherapy in non-metastatic rectal cancer: a propensity score matched analysis.

Eur Radiol. 2024-6

[8]
Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.

Cancer Med. 2023-11

[9]
Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA).

Eur J Surg Oncol. 2023-11

[10]
[Chinese protocol of diagnosis and treatment of colorectal cancer of the National Health Commission (2023 edition)].

Zhonghua Wei Chang Wai Ke Za Zhi. 2023-6-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索